carfilzomib

Carfilzomib (PR-171) is a proteasome inhibitor that irreversibly binds to the chymotrypsin of the 20S proteasome. Carfilzomib has antitumor activity and may be used to treat multiple myeloma.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

CFLZ-567 is a key intermediate for making carfilzomib.

WRR139, a peptide vinyl sulfone, plays a role in disease processes including inflammation and cancer, and acts as an inhibitor of cytosolic enzyme N-glycanase 1 (NGLY1) and Nrf1. Moreover, WRR139 amplifies the cytotoxic effects of Carfilzomib on cancer cells [1].

HRS 4642 is a long-acting, selective KRAS G12D inhibitor with a Kd value of 0.083 nM. It inhibits phosphorylation of downstream MEK and ERK proteins, exhibiting antitumour activity. HRS 4642 reduces target lesions and, when used alone or in combination with Carfilzomib, remodels the tumour microenvironment towards an immunocompetent state.